Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 528 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pharmacokinetic Study in Healthy Volunteers Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Venglustat in Patients With Renal Impairment

NCT03687554
View directory record Official record
Conditions
Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions
Venglustat GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years to 79 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tafenoquine/Chloroquine DDI Study

NCT00871156
View directory record Official record
Conditions
Malaria
Interventions
Chloroquine, Tafenoquine, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

PK Comparison of 6mg and 12mg EMSAM in Elderly vs. Non-Elderly

NCT00532116
View directory record Official record
Conditions
Healthy
Interventions
EMSAM (Selegiline Transdermal System) 6mg, EMSAM (Selegiline Transdermal System) 12mg
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults

NCT07416955
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TPI-120 Pre-Filled Syringe 6 mg/0.6 mL
Biological
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers

NCT03926819
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
HBI-002
Drug
Lead sponsor
Hillhurst Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study With Metformin and Nizatidine

NCT01409395
View directory record Official record
Conditions
Healthy
Interventions
Metformin and nizatidine, Metformin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects

NCT02387866
View directory record Official record
Conditions
Healthy
Interventions
AG-221
Drug
Lead sponsor
Celgene
Industry
Eligibility
20 Years to 50 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability and Pharmacokinetic Parameters of Watermelon (Rind, Flesh and Seeds) Polyphenols

NCT03365960
View directory record Official record
Conditions
Healthy Subjects
Interventions
Watermelon Rind, Watermelon Flesh, Watermelon Seeds, Placebo
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 45 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 4, 2026, 8:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

NCT01359579
View directory record Official record
Conditions
Renal Impairment
Interventions
varespladib methyl
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing

NCT01892891
View directory record Official record
Conditions
Healthy
Interventions
VBY-036
Drug
Lead sponsor
Virobay Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 31, 2013 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)

NCT02031991
View directory record Official record
Conditions
Healthy
Interventions
PF-06439535, Avastin
Biological
Lead sponsor
Pfizer
Industry
Eligibility
21 Years to 55 Years · Male only
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional

Dexpramipexole Renal PK Study

NCT01424176
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Renal Insufficiency
Interventions
Dexpramipexole (dose 1), Dexpramipexole (dose 2)
Drug
Lead sponsor
Knopp Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Brooklyn Center, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2014 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare Two Formulations of Lamotrigine in Healthy Subjects

NCT00410371
View directory record Official record
Conditions
Mental Disorders
Interventions
Lamotrigine, GI267119
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2017 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS

NCT01255709
View directory record Official record
Conditions
Asthma
Interventions
Arm T1: Primatene Mist HFA, Arm T2: Primatene Mist HFA, Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)
Drug
Lead sponsor
Amphastar Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 30 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers

NCT02293148
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863 75 mg, GSK1278863 500 mg, Moxifloxacin 400 mg, Placebo matching GSK1278863, Placebo matching Moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2018 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

MW151-101: First-in-human Study of MW151

NCT04120233
View directory record Official record
Conditions
Drug Toxicity
Interventions
Placebo, MW151, 10mg, MW151, 20mg, MW151, 40mg, MW151, 80mg, MW151, 160mg
Drug
Lead sponsor
Linda Van Eldik
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers

NCT02101216
View directory record Official record
Conditions
Psoriasis
Interventions
Prurisol, Ziagen
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Miami Gardens, Florida
Source: ClinicalTrials.gov public record
Updated Oct 26, 2018 · Synced Oct 4, 2026, 8:55 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study Investigating Lu AG06474 in Healthy Young Participants

NCT05943327
View directory record Official record
Conditions
Healthy Participants
Interventions
Lu AG06474, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))

NCT02237729
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06410293, Adalimumab-US, Adalimumab-EU
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years
Enrollment
362 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
8
States / cities
Coral Gables, Florida • Jacksonville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two AG-881 Formulations and Evaluate the Effect of Food and Omeprazole on the Pharmacokinetics of AG-881

NCT04128787
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AG881 Formulation 1, AG881 Formulation 2, Omeprazole
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

NCT01437384
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura (ITP)
Interventions
E5501
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy Volunteers

NCT03810495
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
naltrexone implant
Drug
Lead sponsor
Go Medical Industries Pty Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Oct 4, 2026, 8:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single-Dose Pharmacokinetics (PK) Study of Novel Neurogenic Compound NSI-189

NCT01310881
View directory record Official record
Conditions
Depression
Interventions
NSI-189 Phosphate
Drug
Lead sponsor
Neuralstem Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2011 · Synced Oct 4, 2026, 8:55 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Dermal Open-Flow Microperfusion and Plasma Pharmacokinetic Study of Multiple Doses of Oral Povorcitinib or Topical Ruxolitinib Cream in Healthy Adult Participants

NCT07588139
View directory record Official record
Conditions
Healthy Participants
Interventions
Povorcitinib, Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 4, 2026, 8:55 PM EDT